This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.

Inclusion Criteria:

• confirmed intrahepatic cholangiocarcinoma
• with Resectable tumor lesion
• no contraindications to surgery
• with high risk of tumour recurrence
• No prior systemic therapy for intrahepatic cholangiocarcinoma.
• ECOG Performance Status of 0 or 1
• Child-Pugh Class: Grade A

Exclusion Criteria:

• History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage
• Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment
• Known genetic or acquired hemorrhage or thrombotic tendency
• Thrombosis or thromboembolic event within 6 months prior to the start of study treatment
• Cardiac clinical symptom or disease that is not well controlled
• Hypertension that can not be well controlled through antihypertensive drugs